Bronchogen
Bronchogen is a synthetic short peptide marketed as a bronchial/respiratory-tissue "bioregulator" within the Khavinson organotropic-peptide tradition, but no peer-reviewed clinical or animal study of this specific product could be located in PubMed/PMC-indexed literature.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
The product is described by its manufacturer as a tetrapeptide (reported composition drawing on alanine, aspartic acid, glutamic acid, and arginine residues) intended to act on bronchial epithelial and pulmonary tissue, following the same organotropic gene-regulation hypothesis used across the Khavinson peptide family: that a short peptide preferentially influences transcriptional activity in the tissue type it was modeled on. This mechanistic framework is supported only by in vitro/animal data on other peptides in the same lineage, not by data on Bronchogen's specific sequence acting on airway or lung cells.
Typical results seen in research
No dedicated clinical trial or animal study of Bronchogen under this name was found in PubMed or PMC. Claims of improved respiratory function, reduced airway inflammation, or bronchoprotective effects are extrapolated from the general Khavinson bioregulator literature and from older Russian research on other, related organ-specific peptide complexes, rather than from direct evidence on this compound. As with the other bioregulators in this group, any respiratory benefit should be regarded as unproven pending compound-specific research.
How it’s commonly used
Bronchogen is typically taken orally as a capsule or tablet, often cycled alongside other Khavinson-tradition bioregulators as part of a general longevity or respiratory-support supplement regimen. It is used in a self-directed research/longevity context and is not an approved respiratory medication.
- Biogerontology · 2010 Peptide bioregulation of aging: results and prospects
- Adv Gerontol · 2012 [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]
- Int J Mol Sci · 2022 Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.